Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: - | CAS number: -
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Skin sensitisation
Administrative data
- Endpoint:
- skin sensitisation: in vivo (LLNA)
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Study period:
- 14 August 2013 to 12 December 2013
- Reliability:
- 1 (reliable without restriction)
- Rationale for reliability incl. deficiencies:
- guideline study
Data source
Reference
- Reference Type:
- study report
- Title:
- Unnamed
- Year:
- 2 013
- Report date:
- 2013
Materials and methods
Test guideline
- Qualifier:
- according to guideline
- Guideline:
- OECD Guideline 429 (Skin Sensitisation: Local Lymph Node Assay)
- Deviations:
- no
- GLP compliance:
- yes
- Type of study:
- mouse local lymph node assay (LLNA)
Test material
- Details on test material:
- - Physical state: extremely viscous amber liquid
- Analytical purity:
- Lot/batch No.: E00031-68-1
- Expiration date of the lot/batch: 16 October 2010
- Storage condition of test material:room temperature in the dark, under nitrogen
Constituent 1
- Specific details on test material used for the study:
- SOURCE OF TEST MATERIAL
- lot/batch No.of test material: E00031-633
- Retest date of the lot/batch: 30 January 2014
- Purity test date: 99%
RADIOLABELLING INFORMATION (if applicable)
This chemical was received from Perkin Elmer Inc., Boston, USA, on 20 February 2013. The chemical was stored refrigerated (2 to 8°C) in the dark in the radiochemistry laboratory at Charles River, Edinburgh. The supplier stated that purity value of the chemical was >97%.
STABILITY AND STORAGE CONDITIONS OF TEST MATERIAL
- Storage condition of test material: In the dark at ambient temperature
In vivo test system
Test animals
- Species:
- mouse
- Strain:
- CBA/Ca
- Sex:
- female
- Details on test animals and environmental conditions:
- TEST ANIMALS
- Source: Charles River UK Limited, Manston Road, Margate, Kent, UK.
- Age at study initiation: 8-12 weeks
- Weight at study initiation: 17.6 g to 21.2 g
- Housing: Housed in pairs in solid-bottomed cages with a stainless steel grid top and integrated food hopper.
- Diet (e.g. ad libitum): ad libitum
- Water (e.g. ad libitum): ad libitum
- Acclimation period: At least 8 days
- Indication of any skin lesions: no
ENVIRONMENTAL CONDITIONS
- Temperature (°C): 21 °C to 23 °C
- Humidity (%): 42% to 63%
- Air changes (per hr): minimum of 10 per hour
- Photoperiod (hrs dark / hrs light): 12 hours light / 12 hours dark (light hours 0700 h to 1900 h)
- IN-LIFE DATES: From: 28 August 2013 To: 16 October 2013
Study design: in vivo (LLNA)
- Vehicle:
- acetone/olive oil (4:1 v/v)
- Concentration:
- 25 µL at 0%, 25%, 50% and 100% formulation concentration
- No. of animals per dose:
- 4 animals per dose
- Details on study design:
- Preliminary tests were conducted as no data on the toxicity or irritancy of the test item was available. Treatment was administered on 3 consecutive days (Days 1 to 3). On each day of treatment the animals received an open application of 25 µL of undiluted test item onto the dorsum of each ear. Doses were administered using an appropriate micropipette.
There was no further treatment after the 3rd application.
Animals were checked for viability early in the morning and again as late as possible on each day. All animals were examined for reaction to treatment. The animals were observed frequently on each day of dosing (predose, immediately post dose and approximately 1 and 2 h after dosing) and once daily thereafter.The body weight of each individual animal was recorded on Day 1 (before the first dose) and on Day 6.
On Day 1 (pre-dose) and on Day 3 (approximately 48 h after the first dose) and Day 6 the thickness of both ears of each mouse was measured using digital callipers. In addition, both ears were observed for erythema and the scores recorded.
Animals were euthanised by cervical dislocation on Day 6 and were then discarded.
The dose concentrations of EXP0700332 indicated below were selected for the main study as suitable non-toxic dosages. Treatment was administered on 3 consecutive days (Days 1 to 3). On each day of treatment the animals received an open application of 25 µL of the appropriate formulation onto the dorsum of each ear. Formulations were administered using an appropriate micropipette. There was no treatment on Days 4 and 5.
On Day 6 each animal received an intravenous injection (250 µL) of phosphate buffered saline (PBS) containing 18.5 µCi of [methyl-3H] thymidine into the lateral tail vein.
Approximately 5 h after intravenous administration, all animals were euthanised by exposure to a rising concentration of carbon dioxide and the major blood vessels were severed to exsanguinate. Each pair of draining auricular lymph nodes was collected from each animal and the animal was then discarded. A single cell suspension of lymph node cells from each paired sample was prepared by gentle disaggregation through a 200 µm mesh stainless steel gauze. The mesh was rinsed with PBS (approximately 1 mL) and discarded. The lymph node cells were then washed (centrifuged at approximately 1300 g for 10 min at 4°C). The supernatant was drawn off, approximately 1 mL PBS was added and the cells were washed (centrifuged) for a second time. The supernatant was discarded and the DNA was precipitated with approximately 1 mL 5% trichloroacetic acid at 2 to 8°C for approximately 21 h. The resulting pellet underwent a further centrifugation and was re-suspended in 200 µL ‘Solvable’, (Perkin Elmer Inc., Waltham, USA) an aqueous-based solubiliser, and the suspension transferred to a vial containing 10 mL scintillation fluid (Aquasafe 500 plus liquid, Zinsser Analytic, Maidenhead, UK). Incorporation of tritiated thymidine was measured by ß-scintillation counting and was expressed as disintegrations per minute (DPM).
Excessive local skin irritation is indicated by an erythema score of 3 and/or an increase in ear thickness of 25% on any day of measurement. - Positive control substance(s):
- hexyl cinnamic aldehyde (CAS No 101-86-0)
Results and discussion
- Positive control results:
- A group of mice was treated with a formulation of hexylcinnamicaldehyde that was prepared at a concentration of 25% in April 2013. This result was considered to provide evidence that the test methods employed at these laboratories are valid.
In vivo (LLNA)
Resultsopen allclose all
- Key result
- Parameter:
- SI
- Value:
- ca. 1
- Test group / Remarks:
- Group 2
- Remarks on result:
- no indication of skin sensitisation based on QSAR/QSPR prediction
- Key result
- Parameter:
- SI
- Value:
- ca. 1.7
- Test group / Remarks:
- Group 3
- Remarks on result:
- no indication of skin sensitisation based on QSAR/QSPR prediction
- Key result
- Parameter:
- SI
- Value:
- ca. 1.8
- Test group / Remarks:
- Group 4
- Remarks on result:
- no indication of skin sensitisation based on QSAR/QSPR prediction
- Key result
- Parameter:
- SI
- Value:
- ca. 1
- Test group / Remarks:
- Group 1
- Remarks on result:
- no indication of skin sensitisation based on QSAR/QSPR prediction
- Cellular proliferation data / Observations:
- DETAILS ON STIMULATION INDEX CALCULATION
Results were corrected for background radiation and expressed as the Stimulation Index (SI). This was obtained by dividing the mean DPM obtained from each group by the mean DPM for the vehicle control group. The SI for the vehicle control group, therefore, is one. A positive response is indicated by an SI =3, together with consideration of dose-response and, where appropriate, statistical significance.
EC3 CALCULATION
The estimated concentration for the test item required to produce a 3-fold increase in draining lymph node cell proliferation (EC3) could not be determined because no group produced a 3-fold increase.
CLINICAL OBSERVATIONS:
There were no systemic signs and no signs of local irritation in any animal during the observation period. Clinical signs were restricted to wetness to the head, which was observed frequently in all animals, including controls. This was considered to be merely vehicle or test formulation residues, and not an adverse clinical sign.
BODY WEIGHTS
Body weights were considered to be unaffected by treatment with EXP0700332 and were acceptable for mice of this age and strain.
Applicant's summary and conclusion
- Interpretation of results:
- GHS criteria not met
- Conclusions:
- Under the conditions of the study, since treatment with EXP0700332 at concentrations of up to 100% did not achieve a stimulation index of =3, it was considered that the test item does
not have the potential to cause skin sensitisation.
Applying the criteria for classification according to the EU labelling regulations Commission Directive 2001/59/EC, no symbol and no risk phrase are required for EXP0700332. - Executive summary:
The objective of this study was to determine the delayed contact hypersensitivity potential of
EXP0700332.
The study was performed using female CBA/Ca mice. A formulation trial showed that acetone:olive oil in a ratio of 4:1, v/v (AOO) was a suitable vehicle for EXP0700332 and that a concentration of 50% was practicable. A preliminary test in two animals was conducted. Each mouse received an open application of 25 µL of undiluted test item onto the dorsum of each ear on 3 consecutive days. There were no signs of either systemic toxicity or local irritation and there was no effect on body weight in either animal.
The animals received 25 µL of the appropriate formulation onto the dorsum of each ear on 3 consecutive days. There were no signs of either systemic toxicity or local irritation and there was no effect on body weight in any animal. Three days after the final application, each animal received an intravenous injection of [methyl-3H] thymidine into the lateral tail vein. Approximately 5 hours later the draining lymph nodes were collected in order that incorporation of tritiated thymidine could be assessed by scintillation counting.
The stimulation indices (SI) for Groups 2, 3 and 4, when compared with Group 1, were 1.0, 1.7 and 1.8, respectively.
Under the conditions of the study, since treatment with EXP0700332 at concentrations of up to 100% did not achieve a stimulation index of 3, it was considered that the test item does not have the potential to cause skin sensitisation.
Applying the criteria for classification according to the Regulation (EC) 1272/2008, no symbol and no risk phrase are required for EXP0700332.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.
Welcome to the ECHA website. This site is not fully supported in Internet Explorer 7 (and earlier versions). Please upgrade your Internet Explorer to a newer version.
This website uses cookies to ensure you get the best experience on our websites.
Find out more on how we use cookies.